MedTrace Logo

Eradication of Malignant Carcinoma in the Breast Tissue

NCT02286778 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-08-03

No results posted yet for this study

Summary

The purpose of this study is to confirm the findings of an early study and expand our knowledge of treating Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor.

Conditions

Interventions

DIETARY_SUPPLEMENT

Acetogenins

Acetogenins BID for 12 months

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Optimal Health Research

    lead OTHER

Principal Investigators

  • John A Shaw, MD · Optimal Health Research

  • Steven Osguthorpe, ND · Optimal Health Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-01-31
Completion
2017-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02286778 on ClinicalTrials.gov